Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-12-27 5:02 pm Sale |
2023-12-22 | 13D | POINT Biopharma Global Inc. PNT |
SILBER ALLAN C | 0 0.000% |
-9,316,184 (Position Closed) |
Filing History |
| 2023-12-20 4:38 pm Sale |
2023-12-18 | 13D | POINT Biopharma Global Inc. PNT |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-17,437,375 (Position Closed) |
Filing History |
| 2023-11-06 1:47 pm Purchase |
2023-11-02 | 13D | POINT Biopharma Global Inc. PNT |
BIOTECHNOLOGY VALUE FUND L P | 17,437,375 16.500% |
8,259,627 (+90.00%) |
Filing History |
| 2023-10-03 2:57 pm Purchase |
2023-10-02 | 13D | POINT Biopharma Global Inc. PNT |
SILBER ALLAN C | 9,316,184 8.800% |
84,816 (+0.92%) |
Filing History |
| 2023-02-14 12:00 pm Purchase |
2022-12-31 | 13G | POINT Biopharma Global Inc. PNT |
BIOTECHNOLOGY VALUE FUND L P | 9,177,748 8.700% |
3,587,700 (+64.18%) |
Filing History |
| 2023-02-03 12:10 pm Purchase |
2022-12-31 | 13G | POINT Biopharma Global Inc. PNT |
BLACKROCK INC BLK |
5,393,438 5.100% |
5,393,438 (New Position) |
Filing History |
| 2022-11-22 4:21 pm Purchase |
2022-11-17 | 13D | POINT Biopharma Global Inc. PNT |
SILBER ALLAN C | 9,231,368 8.740% |
365,580 (+4.12%) |
Filing History |
| 2022-09-26 5:29 pm Sale |
2022-09-26 | 13D | POINT Biopharma Global Inc. PNT |
RA Capital Management, L.P. | 0 0.000% |
-9,003,018 (Position Closed) |
Filing History |
| 2022-09-26 4:54 pm Purchase |
2022-09-14 | 13G | POINT Biopharma Global Inc. PNT |
BIOTECHNOLOGY VALUE FUND L P | 5,590,048 5.400% |
2,669,522 (+91.41%) |
Filing History |
| 2022-09-16 4:29 pm Unchanged |
2022-09-14 | 13D | POINT Biopharma Global Inc. PNT |
RA Capital Management, L.P. | 9,003,018 8.650% |
0 (Unchanged) |
Filing History |
| 2022-08-29 5:01 pm Purchase |
2022-08-25 | 13D | POINT Biopharma Global Inc. PNT |
RA Capital Management, L.P. | 9,003,018 9.900% |
147,000 (+1.66%) |
Filing History |
| 2022-02-14 5:46 pm Purchase |
2021-12-31 | 13G | POINT Biopharma Global Inc. PNT |
PERCEPTIVE ADVISORS LLC | 1,193,995 1.300% |
1,193,995 (New Position) |
Filing History |
| 2022-02-14 4:17 pm Purchase |
2021-12-31 | 13G | Therapeutics Acquisition Corp. RACA |
Boxer Capital LLC | 2,500,000 2.800% |
1,000,000 (+66.67%) |
Filing History |
| 2022-02-14 3:36 pm Purchase |
2021-12-31 | 13G | POINT Biopharma Global Inc. PNT |
RIVERVIEW GROUP LLC | 24,187 0.000% |
24,187 (New Position) |
Filing History |
| 2022-02-14 1:55 pm Unchanged |
2021-12-31 | 13G | POINT Biopharma Global Inc. PNT |
PRICE T ROWE ASSOCIATES INC | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2022-02-11 8:51 pm Purchase |
2021-12-31 | 13G | POINT Biopharma Global Inc. PNT |
BIOTECHNOLOGY VALUE FUND L P | 2,920,526 3.200% |
2,920,526 (New Position) |
Filing History |
| 2022-02-11 5:17 pm Purchase |
2021-12-31 | 13G | POINT Biopharma Global Inc. PNT |
SUVRETTA CAPITAL MANAGEMENT, LLC | 2,672,863 3.000% |
2,672,863 (New Position) |
Filing History |
| 2022-02-11 10:09 am Unchanged |
2021-12-31 | 13G | POINT Biopharma Global Inc. PNT |
AVORO CAPITAL ADVISORS LLC | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2022-02-07 1:46 pm Purchase |
2021-12-31 | 13G | POINT Biopharma Global Inc. PNT |
FRANKLIN RESOURCES INC BEN |
773,700 0.900% |
773,700 (New Position) |
Filing History |
| 2022-02-04 3:47 pm Sale |
2021-12-31 | 13G | Therapeutics Acquisition Corp. RACA |
WELLINGTON MANAGEMENT CO LLP | 0 0.000% |
-877,832 (Position Closed) |
Filing History |